ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

This study is currently recruiting participants.

Verified May 2013 by Amgen

Study NCT01001377 Information provided by Amgen

First Received on October 22, 2009. Last Updated on May 6, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Colorectal Neoplasms

More general conditions related to this trial

Interventions listed in this trial

Additional drug interventions recognized in this trial

Antibodies, Monoclonal
Cetuximab

More general drug interventions related to this trial

Sponsors listed in this trial

Amgen